Navigation Links
DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
Date:10/31/2007

MISSISSAUGA, ON, Oct. 31 /PRNewswire-FirstCall/ - DRAXIS Health Inc. (TSX: DAX) (Nasdaq: DRAX) announces that Dr. Martin Barkin today informed the board of directors that he will retire as the President and Chief Executive Officer of the Company effective December 31, 2007.

Dr. Barkin joined the senior management of DRAXIS in 1992. Over the last fifteen years, he has been instrumental in guiding the Company through a period of significant growth from a small Canadian pharmaceutical marketing company to its current position as a provider of specialized pharmaceutical and radiopharmaceutical products in markets globally.

Brian King, Chair of the board of directors, indicated that, "The Board of Directors wishes to acknowledge and thank Martin for the significant contribution that he has made to the growth and strategic positioning of DRAXIS during his time at the Company and for his dedication to its employees, its goals and its progress over the years. The Board of Directors has commenced a process to identify Dr. Barkin's successor."

With Dr. Barkin's impending retirement, Dan Brazier, presently Chief Operating Officer, will immediately take on the roles and responsibilities currently held by Dr. Barkin until a successor is appointed as President and Chief Executive Officer.

Dr. Barkin said, "I have worked closely together with Dan Brazier for the last several months in the Office of the President and he has been assuming more and more of my responsibilities. I have become very comfortable with his abilities and, therefore, the time was now right for me to inform the board of my intentions to retire at the end of this year."

About DRAXIS Health Inc.:

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc., provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division. DRAXIS employs approximately 500 staff in its Montreal facility.

For additional information please visit http://www.draxis.com

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as contemplated under other applicable securities legislation. These statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "plan," "intend," "believe" or other similar words. These statements discuss future expectations concerning results of operations or financial condition or provide other forward-looking information. Our actual results, performance or achievements could be significantly different from the results expressed in, or implied by, those forward-looking statements. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made.

These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:

- the achievement of desired clinical trial results related to the

Company's pipeline products;

- timely regulatory approval of the Company's products;

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of the Company's products;

- the Company's ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

the Company and its products;

- factors beyond our control that could cause interruptions in our

operations in our single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- the Company's dependence on a small number of key customers;

- the disclosure of confidential information by our collaborators,

employees or consultants;

- the preservation of healthy working relationships with the Company's

union and employees;

- the Company's ability to grow the business;

- the fluctuation of our financial results and exchange and interest

rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against us succeed;

- the volatility of the price of our common shares;

- market acceptance of the Company's products;

- factors described under "Outlook" in the Company's MD&A for the most

recent quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in

the Annual Report Form 20-F filed by the Company with the United

States Securities and Exchange Commission and which is also filed as

the Company's Annual Information Form with Canadian securities

regulators.

For additional information with respect to certain of these and other factors, and relating to the Company generally, reference is made to the Company's most recent filings with the United States Securities and Exchange Commission (available on EDGAR at http://www.sec.gov) and the filings made by the Company with Canadian securities regulators (available on SEDAR at http://www.sedar.com). The forward-looking statements contained in this document represent the Company's expectations as at October 31, 2007. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DRAXIS Health Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Startling Expose – Physicians Often Have No Regular Source Of Health Car
3. Debate Rages over firing of HIV infected health care workers
4. Want a Healthy brew? Have some Tea!
5. Patient’s perception of health status helps in better recover
6. Antioxidants protect health tissue in people undergoing radiation therapy.
7. Sexual abuse affect health for a lifetime
8. Smoking a greater risk than HIV? Yes say health experts!!!!
9. Healthcare sector is now a multi billion-dollar industry in India
10. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
11. How much can exercise improve health?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... More than ... Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. ... for area students and operating support to UNCF-member institutions, including Miles College, Oakwood ...
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... , ... December 02, 2016 , ... With the number ... rehabilitation of an injury, patients must find the one that works for them. When ... he created a machine that worked and decided to share it with others. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of ... 84 percent of parents report speaking with their child about sex related topics, less ... diseases. , Mediaplanet is proud to announce the launch of its second edition of ...
(Date:12/2/2016)... ... 2016 , ... The PAINWeekEnd Regional Conference will be hosted ... Honolulu, offering local frontline clinicians the opportunity to extend their certified continuing medical ... supplemental training related to pain management has surged dramatically in recent years, with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
Breaking Medicine Technology: